{
  "id": 19351820,
  "title": "Septerna Inc stock hits all-time high at 51.54 USD",
  "url": "https://urgent.news/2026/11/10/septerna-inc-stock-hits-all-time-high-at-51-54-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-10T15:21:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/septerna-inc-stock-hits-alltime-high-at-5154-usd-93CH-5016128"
  },
  "original_language": "en",
  "account": "Septerna Inc's stock reached an all-time high of $51.54 per share, signaling a major accomplishment for the company. The stock currently trades at $51.32, falling just 1% short of its 52-week peak. In the past year, the stock has surged by 180%, showcasing impressive growth. Its beta of 2.2 suggests higher volatility compared to the overall market. This rise can be attributed to increased investor confidence and bullish market sentiment towards Septerna Inc. The company's strong market position and growth potential are evident in its performance. However, InvestingPro analysis indicates that the stock might be overvalued at its current price point, positioning it among the most overvalued stocks they monitor. Recent changes in analyst price targets for Septerna Inc. further reflect evolving perceptions of the company's prospects. Guggenheim raised its target to $65, praising advancements in their oral small molecule PTH replacement, SEP-479, and accounting for sales projections from SEP-204, a Graves' disease treatment. Wells Fargo increased its target to $61, highlighting a more optimistic outlook for SEP-479 based on favorable preclinical, commercial, and valuation metrics. H.C. Wainwright set its target at $60 due to positive developments in SEP-479's Phase 1 trial for hypoparathyroidism. Stifel raised its target to $49, noting the successful launch of daily injectable Yorvipath and progress in SEP-479's Phase 1 trials. Guggenheim had previously raised its target to $51, citing promising human half-life data from the drug candidate. These adjustments underscore a growing sense of optimism among analysts regarding Septerna's ongoing research and development initiatives.",
  "summary": null,
  "key_points": [
    "Septerna Inc stock hits all-time high of $51.54 per share",
    "Stock currently trades at $51.32, 1% short of 52-week peak",
    "Analysts optimistic due to SEP-479 advancements and positive preclinical results"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}